Clinical Trials Directory

Trials / Completed

CompletedNCT04592198

Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting

A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film Versus IV Palonosetron 0.25 mg for the Prevention of CINV in Cancer Patients Receiving MEC

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
22 (actual)
Sponsor
Xiamen LP Pharmaceutical Co., Ltd · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV). Subjects receive a single dose of palonosetron prior to moderately emetogenic chemotherapy.

Detailed description

This is a Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film compared to iv injection for moderately emetogenic chemotherapy-induced nausea or vomiting (CINV) in cancer patients. Subjects are randomized into three treatment groups, two with the experimental study drug palonosetron in buccal film at one of two different doses or the control treatment using Palonosetron hydrochloride iv injection. Palonosetron PK will be assessed in a subgroup of each treatment group.

Conditions

Interventions

TypeNameDescription
DRUGPalonosetron Hydrochloride Buccal Film 0.25 MgDose equal to the iv control
DRUGPalonosetron Hydrochloride Buccal Film 0.5 MgDose twice that of iv control
DRUGPalonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solutioniv control

Timeline

Start date
2020-10-01
Primary completion
2021-03-25
Completion
2021-03-25
First posted
2020-10-19
Last updated
2025-03-24
Results posted
2025-03-24

Locations

7 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04592198. Inclusion in this directory is not an endorsement.